Biomarker Study for Prediction of aGVHD

Shanghai Jiao Tong University School of Medicine250 enrolled

Overview

This is a prospective study in patients receiving allogeneic stem cell transplantation. The blood samples on Day-14, -7, 0 and every 7 days until D100 were collected together with clinical data. In the final analysis, cytokines and biomarkers analysis will be carried out and compared between patients in No aGVHD and grade II-IV aGVHD.

This is a prospective study, observation study in patients receiving allogeneic stem cell transplantation in 4 BMT centers in Shanghai. The blood samples (on Day-14, -7, 0 and every 7 days until D100) and clinical data will be collected. In the final analysis, a panel of cytokines and biomarkers analysis of serial blood samples will be carried out and compared between patients with no aGVHD and grade II-IV aGVHD.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

aGVHD

Eligibility

Sex: ALLMin age: 16 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * all patients undergoing allogeneic stem cel transplantation * with informed consent * patients survived without aGVHD or relapse and patients with development of grade II-IV aGVHD Exclusion Criteria: * patients with blood sample and clinical data not available

Locations (1)

Blood & Marrow Transplantation Center, RuiJin Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

incidence of grade II-IV aGVHD

clinical diagnosis and grade of aGVHD

Time frame: 100 days after allogeneic stem cell tansplantation

Central Contacts

Jiong HU, M.D.

CONTACT

86-21-64370045 hj10709@rjh.com.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.